Thesis
Investigation of differentially expressed genes that contribute to therapeutic effects of bevacizumab in BRAF mutant melanoma
- Abstract:
-
Malignant melanoma is a highly aggressive and often lethal disease. In 2012, patient outcomes were poor after resection of high-risk stage II and III melanoma, and vascular endothelial growth factor (VEGF) has been implicated in melanoma progression. The phase III AVAST-M clinical trial (recruiting between 2007-2012) randomized patients with high risk melanoma to 1 year of adjuvant bevacizumab (anti-VEGF antibody) or observation. Patients treated with bevacizumab experienced superior dise...
Expand abstract
Actions
Funding
Cancer Research UK
More from this funder
Bibliographic Details
- Type of award:
- DPhil
- Level of award:
- Doctoral
- Awarding institution:
- University of Oxford
Item Description
Related Items
Terms of use
- Copyright holder:
- Coupe, N
- Copyright date:
- 2020
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record